Genitourinary Cancers | Specialty

Treatment Options for Intermediate/Poor-Risk RCC

March 31st 2020

How to Manage Borderline Intermediate-Risk RCC

March 31st 2020

Favorable-Risk RCC: Options for VEGF TKI Monotherapy

March 31st 2020

Favorable-Risk RCC: Frontline VEGF TKI/IO Combinations

March 31st 2020

Favorable-Risk RCC: Factors in Selecting Therapy

March 31st 2020

Importance of Risk Assessment in Renal Cell Carcinoma

March 31st 2020

Renal Cell Carcinoma: Early Management Strategies

March 31st 2020

Treatment Landscape of Advanced Clear Cell RCC

March 31st 2020

Biology of Clear Cell Renal Cell Carcinoma

March 31st 2020

Cabozantinib Combos Show Potential in Ongoing Advanced RCC Trials

March 30th 2020

Bradley McGregor, MD, discusses the CheckMate-9ER trial in metastatic renal cell carcinoma, as well as the need for future studies in histologies beyond clear cell renal cell carcinoma.

IO/Targeted Combos Poised to Enter Metastatic Urothelial Carcinoma Paradigm

March 26th 2020

Daniel P. Petrylak, MD, discusses the current treatment landscape of metastatic urothelial carcinoma and exciting strategies in the pipeline.

FDA Grants IPI-549 Fast Track Designation in Urothelial Carcinoma

March 25th 2020

The FDA has granted a Fast Track Designation to IPI-549 for use in combination with nivolumab for the treatment of patients with advanced urothelial cancer, according to Infinity Pharmaceuticals, Inc., the manufacturer of the PI3K-gamma inhibitor.

Dr. Drakaki on the Design of the MORPHEUS-mUC Trial in Urothelial Carcinoma

March 25th 2020

Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.

Expert Highlights Shifting Management of Localized Bladder Cancer

March 19th 2020

John P. Sfakianos, MD, discusses some of the optimal and evolving management strategies in localized bladder cancer.

Improvements Needed for Adjuvant Therapy in RCC

March 18th 2020

Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.

Immunotherapy Combinations Are King in Frontline RCC Treatment

March 14th 2020

In metastatic renal cell carcinoma, the use of frontline combination immunotherapy regimens has led to significant survival benefits for patients, and efforts are now being focused on exploring novel options for those who become refractory to this approach.

More Research Required to Define Role of Cytoreductive Nephrectomy in RCC

March 13th 2020

Reza Mehrazin, MD, discusses the need for more research before determining the role of cytoreductive nephrectomy in an era of immunotherapy and targeted therapy.

Dr. Petrylak on Available Treatment Options in Metastatic Bladder Cancer

March 13th 2020

Daniel P. Petrylak, MD, discusses available treatment options in metastatic bladder cancer.

NICE Rejects Pembrolizumab for Urothelial Carcinoma

March 13th 2020

The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend pembrolizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-containing chemotherapy.

Dr. Choueiri on Safety Profile of MK-6482 in Advanced Clear Cell RCC

March 12th 2020

Toni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.